Stonehage Fleming (UK)’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Stonehage Fleming (UK)’s Portfolio GEVA Stock Details GEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-206	Closed	-$19K	–	313
2014 Q4	$19K	Buy	206 +101	+96%	+$7.97K	0.01%	262
2014 Q3	$7K	Sell	105 -200	-66%	-$14.3K	﹤0.01%	305
2014 Q2	$32K	Sell	305 -170	-36%	-$14.5K	0.01%	206
2014 Q1	$39K	Buy	+475	New	+$43.9K	0.02%	272

Other funds holding GEVA

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Stonehage Fleming (UK)'s GEVA Position: Q1 2015 in Review

Stonehage Fleming (UK) sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q1 2015, closing a stake of 206 shares — an estimated $19K sold.

Stonehage Fleming (UK) first reported a position in GEVA in Q1 2014 and held it in 4 quarters. The position peaked at $39K in Q1 2014. 130 funds tracked by Wall St. Rank hold GEVA as of Q1 2015.

Stonehage Fleming (UK) reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q1 2015 after selling out during the quarter.
Stonehage Fleming (UK) sold 206 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q1 2015, an estimated $19K.
Stonehage Fleming (UK) first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q1 2014 and held it in 4 quarters.
Stonehage Fleming (UK)'s SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $39K in Q1 2014.
130 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q1 2015.

Based on Stonehage Fleming (UK)'s 13F filing for Q1 2015, filed 11 Oct 2019.